WO1992021697A3 - Diagnostic peptides derived from m.tuberculosis antigens - Google Patents

Diagnostic peptides derived from m.tuberculosis antigens Download PDF

Info

Publication number
WO1992021697A3
WO1992021697A3 PCT/GB1992/000948 GB9200948W WO9221697A3 WO 1992021697 A3 WO1992021697 A3 WO 1992021697A3 GB 9200948 W GB9200948 W GB 9200948W WO 9221697 A3 WO9221697 A3 WO 9221697A3
Authority
WO
WIPO (PCT)
Prior art keywords
peptides derived
leu
val
pro
tuberculosis
Prior art date
Application number
PCT/GB1992/000948
Other languages
French (fr)
Other versions
WO1992021697A2 (en
Inventor
Hans Vordermeier
David Harris
Carlos Moreno
Juraj Ivanyi
Original Assignee
Medical Res Council
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medical Res Council filed Critical Medical Res Council
Priority to AU17616/92A priority Critical patent/AU667305B2/en
Priority to CA002109822A priority patent/CA2109822A1/en
Publication of WO1992021697A2 publication Critical patent/WO1992021697A2/en
Publication of WO1992021697A3 publication Critical patent/WO1992021697A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
    • C07K16/1289—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Mycobacteriaceae (F)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/35—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Mycobacteriaceae (F)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/23—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a GST-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

The present invention relates to peptides derived from the 38kDa and 19kDa tubercule bacilli protein of M.tuberculosis. One such peptide, 38.G of the sequence (I): Asp-Gln-Val-His-Phe-Gln-Pro-Leu-Pro-Pro-Ala-Val-Val-Lys-Leu-Ser-Asp-Ala-Leu-Ile has been found to be useful for the diagnosis of tuberculosis and provides a basis for a method of distinguishing TB patients from infected or otherwise sensitised but healthy clinical suspects.
PCT/GB1992/000948 1991-05-24 1992-05-26 Diagnostic peptides derived from m.tuberculosis antigens WO1992021697A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU17616/92A AU667305B2 (en) 1991-05-24 1992-05-26 Diagnostic peptides derived from M.tuberculosis antigens
CA002109822A CA2109822A1 (en) 1991-05-24 1992-05-26 Diagnostic peptides derived from m.tuberculosis antigens

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9111291.2 1991-05-24
GB9111291A GB9111291D0 (en) 1991-05-24 1991-05-24 Diagnostic peptides

Publications (2)

Publication Number Publication Date
WO1992021697A2 WO1992021697A2 (en) 1992-12-10
WO1992021697A3 true WO1992021697A3 (en) 1993-05-13

Family

ID=10695577

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB1992/000948 WO1992021697A2 (en) 1991-05-24 1992-05-26 Diagnostic peptides derived from m.tuberculosis antigens

Country Status (5)

Country Link
EP (1) EP0586465A1 (en)
AU (1) AU667305B2 (en)
CA (1) CA2109822A1 (en)
GB (1) GB9111291D0 (en)
WO (1) WO1992021697A2 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7300660B2 (en) 1993-11-23 2007-11-27 The Regents Of The University Of California Abundant extracellular products and methods for their production and use
ES2313719T3 (en) 1993-11-23 2009-03-01 The Regents Of The University Of California ABUNDANT EXTRACELLULAR PRODUCTS AND PROCEDURE OF PRODUCTION AND USE OF THE SAME.
US6752993B1 (en) 1993-11-23 2004-06-22 The Regents Of The University Of California Abundant extracellular product vaccines and methods for their production and use
WO1996041171A1 (en) * 1995-06-07 1996-12-19 Dynagen, Inc. Methods and articles of manufacture for diagnosis of mycobacterial infection
US6290969B1 (en) 1995-09-01 2001-09-18 Corixa Corporation Compounds and methods for immunotherapy and diagnosis of tuberculosis
US6592877B1 (en) 1995-09-01 2003-07-15 Corixa Corporation Compounds and methods for immunotherapy and diagnosis of tuberculosis
WO1997026007A1 (en) * 1996-01-17 1997-07-24 Trustees Of Boston University Mycobacterium antigens and methods for their detection
US6013660A (en) * 1996-10-02 2000-01-11 The Regents Of The University Of California Externally targeted prophylactic and chemotherapeutic method and agents
AU1749397A (en) * 1997-01-17 1998-08-07 Trustees Of Boston University Mycobacterium antigens and methods for their detection
RU2004130304A (en) 2002-03-12 2005-06-10 Хемофарм Концерн А.Д. Фармацеутско-Хемийска Индустрия Вршац (Yu) NEW DIAGNOSTIC METHOD FOR SPECTROSCOPIC DIAGNOSTICS OF TUBERCULOSIS AND DIAGNOSTIC SET
ITRM20040091A1 (en) 2004-02-19 2004-05-19 Istituto Naz Per Le Malattie QUICK IMMUNOLOGICAL TEST FOR DIAGNOSIS AND MONITORING OF TUBERCULAR INFECTION.

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1988006591A1 (en) * 1987-02-26 1988-09-07 Scripps Clinic And Research Foundation Mycobacterial recombinants and peptides
EP0419355A1 (en) * 1989-09-19 1991-03-27 N.V. Innogenetics S.A. Recombinant polypeptides and peptides, nucleic acids coding for the same and use of these polypeptides and peptides in the diagnostic of tuberculosis

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1988006591A1 (en) * 1987-02-26 1988-09-07 Scripps Clinic And Research Foundation Mycobacterial recombinants and peptides
EP0419355A1 (en) * 1989-09-19 1991-03-27 N.V. Innogenetics S.A. Recombinant polypeptides and peptides, nucleic acids coding for the same and use of these polypeptides and peptides in the diagnostic of tuberculosis

Non-Patent Citations (13)

* Cited by examiner, † Cited by third party
Title
EUROPEAN JOURNAL OF IMMUNOLOGY vol. 18, June 1988, WEINHEIM, FRG pages 973 - 976 J.R. LAMB ET AL. 'Prediction and identification of an HLA-DR-restricted T cell determinant in the 19-kDa protein of Mycobacterium tuberculosis' *
IMMUNOLOGY vol. 74, no. 1, September 1991, OXFORD, GB pages 1 - 7 A. FAITH ET AL. 'Analysis of human T-cell epitopes in the 19,000 MW antigen of Mycobacterium tuberculosis: influence of HLA-DR' cited in the application *
Infection and Immunity, vol. 51, no. 1, January 1986, (Washington, DC, US), H.D. ENGERS et al.: "Results of a world health organization-sponsored workshop to characterize antigens recognized by Mycobacterium-specific monoclonal antibodies", pages 718-720 *
Infection and Immunity, vol. 54, no. 1, October 1986, (Washington, DC, US), D. YOUNG et al.: "Immunological activity of a 38-kilodalton protein purified from Mycobacterium tuberculosis", pages 177-183 *
Infection and Immunity, vol. 57, no. 8, August 1989, (Washington, DC, US), A.B. ANDERSEN et al.: "Structure and mapping of antigenic domains of protein antigen b, a 38,000-molecular-weight protein of Mycobacterium tuberculosis", pages 2481-2488, see abstract; figures 5,7 *
INFECTION AND IMMUNITY. vol. 54, no. 1, October 1986, WASHINGTON US pages 177 - 183 D. YOUNG ET AL. 'Immunological activity of a 38-kilodalton protein purified from Mycobacterium tuberculosis.' *
INFECTION AND IMMUNITY. vol. 57, no. 8, August 1989, WASHINGTON US pages 2481 - 2488 A. B. ANDERSEN & E. B. HANSEN 'Structure and Mapping of Antigenic Domains of Protein Antigen b, a 38,000-Molecular-Weight Protein of Mycobacterium tuberculosis' *
JOURNAL OF IMMUNOLOGY vol. 147, no. 8, 15 October 1991, BALTIMORE US pages 2706 - 2712 D.P. HARRIS ET AL. 'MURINE T CELL-STIMULATORY PEPTIDES FROM THE 19-kDa ANTIGEN OF MYCOBACTERIUM TUBERCULOSIS' cited in the application *
JOURNAL OF IMMUNOLOGY vol. 148, no. 7, 1 April 1992, BALTIMORE US pages 2248 - 2255 K.R. ASHBRIDGE ET AL. 'MAPPING OF T HELPER CELL EPITOPES BY USING PEPTIDES SPANNING THE 19-kDa PROTEIN OF MYCOBACTERIUM TUBERCULOSIS' cited in the application *
JOURNAL OF IMMUNOLOGY. vol. 147, no. 3, 1 August 1991, BALTIMORE US pages 1023 - 1029 H. M. VORDERMEIER ET AL. 'IDENTIFICATION OF T CELL STIMULATORY PEPTIDES FROM THE 38-kDa PROTEIN OF Mycobacterium tuberculosis' *
Nucleic Acids Research, vol. 17, no. 3, 11 February 1989, (Arlington, Virginia, US), K.R. ASHBRIDGE et al.: "Nucleotide sequence of the 19 kDa antigen gene from Mycobacterium tuberculosis", page 1249 *
NUCLEIC ACIDS RESEARCH. vol. 17, no. 3, 11 February 1989, ARLINGTON, VIRGINIA US page 1249 K. R. ASHBRIDGE ET AL. 'Nucleotide sequence of the 19 kDa antigen gene from Mycobacterium tuberculosis' *
The Journal of Immunology, vol. 147, no. 3, 1 August 1991, (Baltimore, US), H.M. VORDERMEIER et al.: "Identification of T cell stimulatory peptides from the 38-kDa protein of Mycobacterium tuberculosis", pages 1023-1029, see the whole document *

Also Published As

Publication number Publication date
EP0586465A1 (en) 1994-03-16
AU1761692A (en) 1993-01-08
GB9111291D0 (en) 1991-07-17
CA2109822A1 (en) 1992-12-10
WO1992021697A2 (en) 1992-12-10
AU667305B2 (en) 1996-03-21

Similar Documents

Publication Publication Date Title
EP0909814A3 (en) Use of protein kinases for the diagnosis and treatment of Alzheimer's disease
ATE108662T1 (en) ANTIMICROBIAL PEPTIDES, COMPOSITIONS CONTAINING SAME AND USES THEREOF.
CA2180950A1 (en) Kallikrein-inhibiting "kunitz domain" proteins and analogues thereof
EP1484339A3 (en) Kallikrein-inhibiting "Kunitz Domain" proteins and nucleic acids encoding the same
WO1992021697A3 (en) Diagnostic peptides derived from m.tuberculosis antigens
WO1996003502A3 (en) Muc1 derived proteins for the diagnosis, imaging and therapy of human cancer
SI0820303T1 (en) PEPTIDE p277 ANALOGS, AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM FOR TREATMENT OR DIAGNOSIS OF DIABETES
HUP9901688A2 (en) Novel peptides derived from human heat shock protein 60 for treatment of diabetes, compositions, methods and kits
EP0674661A4 (en) Assay and treatment for demyelinating diseases such as multiple sclerosis.
GR3022052T3 (en) Dna sequences which code for virulence characteristics of --(streptococcus suis) and parts thereof, polypeptides and antibodies derived therefrom and the use thereof for the diagnosis of and protection against infection by --(s. suis) in mammals, including man
HK1031994A1 (en) Methods for detection and treatment of individuals having abnormal cells expressing hla-a2/tyrosinase peptide antigens
CA2184175A1 (en) Isolated, tyrosinase derived peptides and uses thereof
WO1993021321A3 (en) T CELL EPITOPES OF THE MAJOR ALLERGENS FROM $i(AMBROSIA ARTEMISIIFOLIA)
NO912391D0 (en) CASE INFRASTRUCTURE FOR THERAPEUTIC, PROPHYLACTIC AND / OR DIAGNOSTIC APPLICATION FOR INFECTIONS IN THE BREATHING ORGANIZATIONS.
NO983238L (en) Exodus chemokine materials and methods
AU2579995A (en) Alpha b crystallin for use in diagnosis and therapy of auto-immune diseases in particular multiple sclerosis
DE69521985D1 (en) DIAGNOSIS AND TREATMENT OF STREPTOCOCUS OR ENTEROCOCUS INFECTIONS
DE69326145D1 (en) SYNTHETIC PEPTIDES FOR THE TREATMENT OF MYASTHENIA GRAVIS
NO941458L (en)
ZA9510828B (en) Peptide p277 analogs and phamarceutical compositions comprising them for treatment or diagnosis of diabetes
KR960037695A (en) Peptides comprising epitopes of 60kDa and 52kDa Ro / SSA antigens that can be used for the diagnosis of systemic lupus erythematosus
CA2151945A1 (en) Assay and treatment for demyelinating diseases such as multiple sclerosis

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AT AU BB BG BR CA CH CS DE DK ES FI GB HU JP KP KR LK LU MG MW NL NO PL RO RU SD SE US

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE BF BJ CF CG CH CI CM DE DK ES FR GA GB GN GR IT LU MC ML MR NL SE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AT AU BB BG BR CA CH CS DE DK ES FI GB HU JP KP KR LK LU MG MW NL NO PL RO RU SD SE US

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE BF BJ CF CG CH CI CM DE DK ES FR GA GB GN GR IT LU MC ML MR NL SE SN TD TG

ENP Entry into the national phase

Ref document number: 1993 142424

Country of ref document: US

Date of ref document: 19931122

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 1992910821

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2109822

Country of ref document: CA

WWP Wipo information: published in national office

Ref document number: 1992910821

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 1992910821

Country of ref document: EP